Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Resource Type
Article
Authors
Ren, Zhenggang ; Xu, Jianming ; Bai, Yuxian ; Xu, Aibing ; Cang, Shundong ; Du, Chengyou ; Li, Qiu ; Lu, Yinying ; Chen, Yajin ; Guo, Yabing ; Chen, Zhendong ; Liu, Baorui ; Jia, Weidong ; Wu, Jian ; Wang, Junye ; Shao, Guoliang ; Zhang, Bixiang ; Shan, Yunfeng ; Meng, Zhiqiang ; Wu, Jianbing ; Gu, Shanzhi ; Yang, Wei ; Liu, Chao ; Shi, Xuetao ; Gao, Zhenyuan ; Yin, Tao ; Cui, Jiuwei ; Huang, Ming ; Xing, Baocai ; Mao, Yilei ; Teng, Gaojun ; Qin, Yanru ; Wang, Jinhai ; Xia, Feng ; Yin, Guowen ; Yang, Yong ; Chen, Mingxia ; Wang, Yan ; Zhou, Hui ; Fan, Jia
Source
In The Lancet Oncology July 2021 22(7):977-990
Subject
Primary Research Articles
Language
ISSN
1470-2045